Enrolling in a clinical trial can be a rewarding experience, but for many, it involves complex information, unfamiliar procedures, and a significant time commitment. Throughout
The way drugs are manufactured has undergone significant change over the past several years. Many biopharmaceutical companies now rely on distributed manufacturing models, where multiple
Over the last decade, regulators have encouraged sponsors to adopt risk-based monitoring (RBM) as a way to improve trial oversight and focus attention where it
Receiving a Form FDA 483 can put a lot of pressure on your biopharma organization. Once an inspection is complete, teams are often working against
Representative enrollment has been a core component of clinical research for years, but with the passage of the Food and Drug Omnibus Reform Act, it’s
The adoption of ICH E6(R3) has led many organizations to update their Standard Operating Procedures (SOPs) and focus more on risk-based monitoring, but one of
We use cookies to enhance site functionality, analyze traffic, and improve your browsing experience. You can accept all cookies, reject non-essential ones, or manage your preferences at any time. For more details, please see our Privacy Policy.
